---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-006019"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2024-01-24T23:59:59+00:00"
generated_at: "2026-06-06T19:17:53.299208+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics receives FDA SPA agreement for NORSE EIGHT trial; announces up to $172M private placement

## Summary
- FDA agreed under SPA to NORSE EIGHT non-inferiority trial (~400 wet AMD subjects); primary endpoint BCVA change at 8 weeks.
- Private placement of up to $60M in common stock plus warrants for up to $99M additional proceeds upon cash exercise.
- Existing note amended: maturity extended to July 1, 2025; conversion price reduction on $15M principal tied to qualified offering.
- Closing conditioned on stockholder approval of share increase, reverse split, and Nasdaq Rule 5635(d) approval; expected Q1 2024.
- Proceeds to fund NORSE EIGHT, other ONS-5010 development, working capital; BLA resubmission targeted by end of CY2024.

## SEC filing metadata
- accession: 0001104659-24-006019
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2024-01-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465924006019/0001104659-24-006019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465924006019/tm243921d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-006019
- JSON: https://secwatch.observer/filing/0001104659-24-006019.json
- Plain text: https://secwatch.observer/filing/0001104659-24-006019.txt

## Key facts
- Material Agreements
  Outlook Therapeutics, Inc. entered into Securities Purchase Agreement with the institutional and accredited investors named therein valued at $60 million (effective 2024-01-22).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the institutional and accredited investors named therein
  - Value: $60 million
  - Effective: 2024-01-22
  source text: On January 22, 2024, Outlook Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with the institutional and accredited investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, and the Investors agreed to purchase, in a private placement (the “Private Placement”) an aggregate of $60 million in shares
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465924006019/0001104659-24-006019-index.htm
- Material Agreements
  Outlook Therapeutics, Inc. entered into Registration Rights Agreement with the Investors (effective 2024-01-22).
  - Action: entry
  - Counterparty: the Investors
  - Effective: 2024-01-22
  source text: Also on January 22, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465924006019/0001104659-24-006019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.